trending Market Intelligence /marketintelligence/en/news-insights/trending/h9nycfqqp4gjfp_ycw3-1g2 content esgSubNav
In This List

Arbutus Biopharma settles licensing case with Acuitas Therapeutics

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Arbutus Biopharma settles licensing case with Acuitas Therapeutics

Arbutus Biopharma Corp. settled a licensing case with Acuitas Therapeutics before trial.

The case, filed by Acuitas in the Supreme Court of British Columbia, involves Arbutus' lipid nanoparticle, or LNP, technology, which delivers drugs through tiny particles of fat or oil that travel through the bloodstream.

Acuitas signed a cross license agreement for the technology in 2012, and the suit centered on whether that deal gave the private biotechnology company rights to use and sublicense Arbutus' pre-2010 LNP technology.

The settlement terminates Acuitas' right to use or sublicense Arbutus LNP technology, building on a prior injunction that prevented Acuitas from further providing Arbutus LNP technology to any third party.

Canada-based biotechnology company Arbutus is developing drugs for chronic hepatitis B infection, in addition to licensing its LNP technology to industry partners.